All News

pill,ASA,colchcine,small

Does Colchicine Lower Gout Mortality Risk?

Jack Cush, MD

Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.

Read Article
shingles_0.jpg

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab

MedPage Today

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.

Read Article
psA.fil_.toes_.jpg

Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis

Jack Cush, MD

Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.

Read Article
RheumNow Podcast square

ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Read Article
lupus,nephritis,GN

Best of 2024: Upside/Downside of Steroids in Lupus Nephritis

Jack Cush, MD

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis demonstrates both the benefits and harms to early glucocorticoid regimens on lupus outcomes.

Read Article
Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4 https://t.co/CBHxzBc9XQ
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis (PsA).… https://t.co/yKBV91dR8z https://t.co/nndnpYheNu
Dr. John Cush RheumNow ( View Tweet)
12 mos study of RCT 179 gout pts starting allopurinol finds that betw mos 6-12, gout flares went down. 38% had no flares, 19% had 1 flare, & 43% had >1 flare in 2nd 6 mos. # flares equates to control and impact of gout on outcomes. https://t.co/TMwXZStbJU

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologist Survey: Active Lupus on pred + DMARD w/ (more than skin/Joint) organ & serologic activity- whats your preferred "add-on" drug?

Dr. John Cush RheumNow ( View Tweet)

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/aNk5pgBpiJ https://t.co/C427ayULng

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency https://t.co/Fkn26crcNX https://t.co/LJVa0TApid

Links:

Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V

Links:

Dr. John Cush RheumNow ( View Tweet)
post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8 https://t.co/tB9sd9VS1K

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors are effective at repigmentation in vitiligo. 5 RCTs, 1,550 pts showed >50% improvement (TVASI50; RR 2.67) or >75% (FVASI75; RR 3.97_ JAKi increased skin AE, but not significantly different from placebo pts. https://t.co/zIreYlUyLt https://t.co/pCWKL2vSVs

Links:

Dr. John Cush RheumNow ( View Tweet)
Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Metanalysis of 10 studies shows reactivation in 21% of HBsAg+ patients without prophylaxis vs 4.4% in HBsAg−/HBcAb+ patients. https://t.co/eHzIeA8uJK https://t.co/CmZw8C8ibn

Links:

Dr. John Cush RheumNow ( View Tweet)
Outcomes Comparison study of late-onset RA (LORA) vs younger-onset RA (YORA) showed similar Dz activity assessments over 5 years but Late onset RA had worse functional outcomes and more adverse events (adj HR 4.7 for death & 2.6 for malignancy). https://t.co/b58zJG1OuA https://t.co/WZa12O06Rf

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/zLxEOnWjpB https://t.co/I8jBcxO6rH

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency https://t.co/atoMR1YChT https://t.co/OeaF9QUGEz

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Eli Lilly’s GLP-1 drug Zepbound [tirzepatide] to treat moderate to severe obstructive sleep apnea in adults with obesity in combination with increased physical activity and a reduced-calorie diet.” https://t.co/rYiM6JzmDX https://t.co/hO6CgH9pVs

Links:

Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×